Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 229

1.

STREAM: a pragmatic and explanatory trial for MDR-TB treatment.

Abubakar I, Meredith S, Nunn AJ, Phillips PPJ, Rusen ID.

Lancet Infect Dis. 2019 Jun;19(6):575-576. doi: 10.1016/S1473-3099(19)30215-4. No abstract available.

PMID:
31122769
2.

Cost-effectiveness of intrapleural use of tissue plasminogen activator and DNase in pleural infection: Evidence from the MIST2 randomised controlled trial.

Luengo-Fernandez R, Penz E, Dobson M, Psallidas I, Nunn AJ, Maskell NA, Rahman NM.

Eur Respir J. 2019 May 16. pii: 1801550. doi: 10.1183/13993003.01550-2018. [Epub ahead of print]

PMID:
31097519
3.

Linezolid for drug-susceptible tuberculosis.

Ahmed S, Moore DA, Nimmo C, Nunn AJ, Yates TA; North London TB Journal Club.

Lancet Infect Dis. 2019 Apr;19(4):357. doi: 10.1016/S1473-3099(19)30110-0. Epub 2019 Mar 27. No abstract available.

PMID:
30938294
4.

Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape.

Phillips PPJ, Mitnick CD, Neaton JD, Nahid P, Lienhardt C, Nunn AJ.

PLoS Med. 2019 Mar 22;16(3):e1002767. doi: 10.1371/journal.pmed.1002767. eCollection 2019 Mar.

5.

A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.

Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, van Deun A, Dat PT, Lan N, Master I, Mebrahtu T, Meressa D, Moodliar R, Ngubane N, Sanders K, Squire SB, Torrea G, Tsogt B, Rusen ID; STREAM Study Collaborators.

N Engl J Med. 2019 Mar 28;380(13):1201-1213. doi: 10.1056/NEJMoa1811867. Epub 2019 Mar 13.

6.

Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study.

Murphy ME, Wills GH, Murthy S, Louw C, Bateson ALC, Hunt RD, McHugh TD, Nunn AJ, Meredith SK, Mendel CM, Spigelman M, Crook AM, Gillespie SH; REMoxTB consortium.

BMC Med. 2018 Oct 17;16(1):189. doi: 10.1186/s12916-018-1169-5.

7.

Toxicity associated with tuberculosis chemotherapy in the REMoxTB study.

Tweed CD, Crook AM, Amukoye EI, Dawson R, Diacon AH, Hanekom M, McHugh TD, Mendel CM, Meredith SK, Murphy ME, Murthy SE, Nunn AJ, Phillips PPJ, Singh KP, Spigelman M, Wills GH, Gillespie SH.

BMC Infect Dis. 2018 Jul 11;18(1):317. doi: 10.1186/s12879-018-3230-6.

8.

Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis.

Murthy SE, Chatterjee F, Crook A, Dawson R, Mendel C, Murphy ME, Murray SR, Nunn AJ, Phillips PPJ, Singh KP, McHugh TD, Gillespie SH; REMoxTB Consortium.

BMC Med. 2018 May 21;16(1):73. doi: 10.1186/s12916-018-1053-3.

9.

Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study.

Tweed CD, Wills GH, Crook AM, Dawson R, Diacon AH, Louw CE, McHugh TD, Mendel C, Meredith S, Mohapi L, Murphy ME, Murray S, Murthy S, Nunn AJ, Phillips PPJ, Singh K, Spigelman M, Gillespie SH.

BMC Med. 2018 Mar 28;16(1):46. doi: 10.1186/s12916-018-1033-7.

10.

Accuracy of intravenous and enteral preparations involving small volumes for paediatric use: a review.

Ainscough LP, Ford JL, Morecroft CW, Peak M, Turner MA, Nunn AJ, Roberts M.

Eur J Hosp Pharm Sci Pract. 2018 Mar;25(2):66-71. doi: 10.1136/ejhpharm-2016-001117. Epub 2017 Jan 4. Review.

11.

A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens.

Phillips PPJ, Mendel CM, Nunn AJ, McHugh TD, Crook AM, Hunt R, Bateson A, Gillespie SH.

BMC Med. 2017 Nov 24;15(1):207. doi: 10.1186/s12916-017-0955-9.

12.

Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis.

Murphy ME, Phillips PPJ, Mendel CM, Bongard E, Bateson ALC, Hunt R, Murthy S, Singh KP, Brown M, Crook AM, Nunn AJ, Meredith SK, Lipman M, McHugh TD, Gillespie SH; REMoxTB Consortium.

BMC Med. 2017 Oct 27;15(1):192. doi: 10.1186/s12916-017-0947-9.

13.

Doxycycline compared with prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial.

Mason JM, Chalmers JR, Godec T, Nunn AJ, Kirtschig G, Wojnarowska F, Childs M, Whitham D, Schmidt E, Harman K, Walton S, Chapman A, Williams HC; U.K. Dermatology Clinical Trials Network BLISTER Study Group.

Br J Dermatol. 2018 Feb;178(2):415-423. doi: 10.1111/bjd.16006. Epub 2018 Jan 15.

14.

Randomized Controlled Trial of Urokinase versus Placebo for Nondraining Malignant Pleural Effusion.

Mishra EK, Clive AO, Wills GH, Davies HE, Stanton AE, Al-Aloul M, Hart-Thomas A, Pepperell J, Evison M, Saba T, Harrison RN, Guhan A, Callister ME, Sathyamurthy R, Rehal S, Corcoran JP, Hallifax R, Psallidas I, Russell N, Shaw R, Dobson M, Wrightson JM, West A, Lee YCG, Nunn AJ, Miller RF, Maskell NA, Rahman NM.

Am J Respir Crit Care Med. 2018 Feb 15;197(4):502-508. doi: 10.1164/rccm.201704-0809OC. Erratum in: Am J Respir Crit Care Med. 2018 Apr 15;197(8):1092-1093.

PMID:
28926296
15.

The BLISTER study: possible overestimation of tetracycline efficacy - Authors' reply.

Williams HC, Chalmers JR, Nunn AJ, Kirtschig G, Schmidt E.

Lancet. 2017 Aug 19;390(10096):735-736. doi: 10.1016/S0140-6736(17)31790-7. No abstract available.

PMID:
28831990
16.

A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.

Chalmers JR, Wojnarowska F, Kirtschig G, Mason J, Childs M, Whitham D, Harman K, Chapman A, Walton S, Schmidt E, Godec TR, Nunn AJ, Williams HC.

Health Technol Assess. 2017 Mar;21(10):1-90. doi: 10.3310/hta21100.

17.

A Comprehensive List of Items to be Included on a Pediatric Drug Monograph.

Kelly LE, Ito S, Woods D, Nunn AJ, Taketomo C, de Hoog M, Offringa M.

J Pediatr Pharmacol Ther. 2017 Jan-Feb;22(1):48-59. doi: 10.5863/1551-6776-22.1.48.

18.

Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial.

Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E, Chalmers JR, Childs M, Walton S, Harman K, Chapman A, Whitham D, Nunn AJ; UK Dermatology Clinical Trials Network BLISTER Study Group.

Lancet. 2017 Apr 22;389(10079):1630-1638. doi: 10.1016/S0140-6736(17)30560-3. Epub 2017 Mar 6. Erratum in: Lancet. 2017 Oct 28;390(10106):1948.

19.

Development of the Liverpool Adverse Drug Reaction Avoidability Assessment Tool.

Bracken LE, Nunn AJ, Kirkham JJ, Peak M, Arnott J, Smyth RL, Pirmohamed M, Turner MA.

PLoS One. 2017 Jan 3;12(1):e0169393. doi: 10.1371/journal.pone.0169393. eCollection 2017.

20.

A systematic review of the use of dosage form manipulation to obtain required doses to inform use of manipulation in paediatric practice.

Richey RH, Hughes C, Craig JV, Shah UU, Ford JL, Barker CE, Peak M, Nunn AJ, Turner MA.

Int J Pharm. 2017 Feb 25;518(1-2):155-166. doi: 10.1016/j.ijpharm.2016.12.032. Epub 2016 Dec 28. Review.

PMID:
28040560
21.

Efficacy and safety of regimens for drug-resistant tuberculosis.

Yates TA, Nunn AJ.

Lancet Infect Dis. 2016 Nov;16(11):1218-1219. doi: 10.1016/S1473-3099(16)30390-5. No abstract available.

PMID:
27788973
22.

Product Substitution as a Way Forward in Avoiding Potentially Harmful Excipients in Neonates.

Nellis G, Metsvaht T, Varendi H, Lass J, Duncan J, Nunn AJ, Turner MA, Lutsar I.

Paediatr Drugs. 2016 Jun;18(3):221-30. doi: 10.1007/s40272-016-0173-5.

PMID:
27099961
23.

Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.

Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta R, Harausz E, Harrington M, Horsburgh CR, Lienhardt C, McNeeley D, Mitnick CD, Nachman S, Nahid P, Nunn AJ, Phillips P, Rodriguez C, Shah S, Wells C, Thomas-Nyang'wa B, du Cros P.

Int J Tuberc Lung Dis. 2016 Mar;20(3):290-4. doi: 10.5588/ijtld.15.0490.

24.

Essential medicines containing ethanol elevate blood acetaldehyde concentrations in neonates.

Pandya HC, Mulla H, Hubbard M, Cordell RL, Monks PS, Yakkundi S, McElnay JC, Nunn AJ, Turner MA; ESNEE consortium.

Eur J Pediatr. 2016 Jun;175(6):841-7. doi: 10.1007/s00431-016-2714-x. Epub 2016 Mar 21.

25.

Erratum to: Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.

Phillips PP, Mendel CM, Burger DA, Crook AM, Nunn AJ, Dawson R, Diacon AH, Gillespie SH.

BMC Med. 2016 Feb 23;14:36. doi: 10.1186/s12916-016-0585-7. No abstract available.

26.

Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.

Phillips PP, Mendel CM, Burger DA, Crook AM, Nunn AJ, Dawson R, Diacon AH, Gillespie SH.

BMC Med. 2016 Feb 4;14:19. doi: 10.1186/s12916-016-0565-y. Erratum in: BMC Med. 2016;14:36. Crook, Angela [corrected to Crook, Angela M].

27.

Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion: The TIME1 Randomized Clinical Trial.

Rahman NM, Pepperell J, Rehal S, Saba T, Tang A, Ali N, West A, Hettiarachchi G, Mukherjee D, Samuel J, Bentley A, Dowson L, Miles J, Ryan CF, Yoneda KY, Chauhan A, Corcoran JP, Psallidas I, Wrightson JM, Hallifax R, Davies HE, Lee YC, Dobson M, Hedley EL, Seaton D, Russell N, Chapman M, McFadyen BM, Shaw RA, Davies RJ, Maskell NA, Nunn AJ, Miller RF.

JAMA. 2015 Dec 22-29;314(24):2641-53. doi: 10.1001/jama.2015.16840. Erratum in: JAMA. 2016 Feb 16;315(7):707. JAMA. 2016 Apr 19;315(15):1661.

PMID:
26720026
28.

Reducing relapse in tuberculosis treatment.

Nunn AJ, Phillips PP, Abubakar I.

Int J Tuberc Lung Dis. 2015 Oct;19(10):1263-4. doi: 10.5588/ijtld.15.0518. No abstract available.

PMID:
26459549
29.

A multicentre randomised controlled trial and economic evaluation of continuous positive airway pressure for the treatment of obstructive sleep apnoea syndrome in older people: PREDICT.

McMillan A, Bratton DJ, Faria R, Laskawiec-Szkonter M, Griffin S, Davies RJ, Nunn AJ, Stradling JR, Riha RL, Morrell MJ.

Health Technol Assess. 2015 Jun;19(40):1-188. doi: 10.3310/hta19400.

30.

Effect of CPAP on Cardiac Function in Minimally Symptomatic Patients with OSA: Results from a Subset of the MOSAIC Randomized Trial.

Craig S, Kylintireas I, Kohler M, Nicoll D, Bratton DJ, Nunn AJ, Leeson P, Neubauer S, Stradling JR.

J Clin Sleep Med. 2015 Sep 15;11(9):967-73. doi: 10.5664/jcsm.5004.

31.

What is a pragmatic clinical trial?

Williams HC, Burden-Teh E, Nunn AJ.

J Invest Dermatol. 2015 Jun;135(6):1-3. doi: 10.1038/jid.2015.134. No abstract available.

32.

High variability in the dosing of commonly used antibiotics revealed by a Europe-wide point prevalence study: implications for research and dissemination.

Metsvaht T, Nellis G, Varendi H, Nunn AJ, Graham S, Rieutord A, Storme T, McElnay J, Mulla H, Turner MA, Lutsar I.

BMC Pediatr. 2015 Apr 16;15:41. doi: 10.1186/s12887-015-0359-y.

33.

Potentially harmful excipients in neonatal medicines: a pan-European observational study.

Nellis G, Metsvaht T, Varendi H, Toompere K, Lass J, Mesek I, Nunn AJ, Turner MA, Lutsar I; ESNEE consortium.

Arch Dis Child. 2015 Jul;100(7):694-9. doi: 10.1136/archdischild-2014-307793. Epub 2015 Apr 8.

PMID:
25854872
34.

A randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0.5 mg kg(-1) daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Trial.

Chalmers JR, Wojnarowska F, Kirtschig G, Nunn AJ, Bratton DJ, Mason J, Foster KA, Whitham D, Williams HC; BLISTER study group.

Br J Dermatol. 2015 Jul;173(1):227-34. doi: 10.1111/bjd.13729. Epub 2015 May 26.

PMID:
25683592
35.

ADRIC: Adverse Drug Reactions In Children – a programme of research using mixed methods.

Smyth RL, Peak M, Turner MA, Nunn AJ, Williamson PR, Young B, Arnott J, Bellis JR, Bird KA, Bracken LE, Conroy EJ, Cresswell L, Duncan JC, Gallagher RM, Gargon E, Hesselgreaves H, Kirkham JJ, Mannix H, Smyth RMD, Thiesen S, Pirmohamed M.

Southampton (UK): NIHR Journals Library; 2014 Jun.

36.

Clinical coding of prospectively identified paediatric adverse drug reactions--a retrospective review of patient records.

Bellis JR, Kirkham JJ, Nunn AJ, Pirmohamed M.

BMC Pharmacol Toxicol. 2014 Dec 17;15:72. doi: 10.1186/2050-6511-15-72.

37.

Sleep apnoea in the elderly - authors' reply.

McMillan A, Bratton DJ, Faria R, Laskawiec-Szkonter M, Griffin S, Nunn AJ, Stradling JR, Riha RL, Morrell MJ.

Lancet Respir Med. 2014 Nov;2(11):e21-e22. doi: 10.1016/S2213-2600(14)70240-1. Epub 2014 Nov 3. No abstract available.

PMID:
25439572
38.

Short intensified treatment in children with drug-susceptible tuberculous meningitis.

Turkova A, Seddon JA, Nunn AJ, Gibb DM, Phillips PP.

Pediatr Infect Dis J. 2014 Sep;33(9):993. doi: 10.1097/INF.0000000000000371. No abstract available.

39.

High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.

Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA; RIFAQUIN Trial Team.

N Engl J Med. 2014 Oct 23;371(17):1599-608. doi: 10.1056/NEJMoa1314210.

40.

Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis.

Nunn AJ, Cook SV, Burgos M, Rigouts L, Yorke-Edwards V, Anyo G, Kim SJ, Enarson DA, Jindani A, Lienhardt C; Study C team.

Int J Tuberc Lung Dis. 2014 Oct;18(10):1252-4. doi: 10.5588/ijtld.14.0281.

PMID:
25216842
41.

Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.

Nunn AJ, Rusen ID, Van Deun A, Torrea G, Phillips PP, Chiang CY, Squire SB, Madan J, Meredith SK.

Trials. 2014 Sep 9;15:353. doi: 10.1186/1745-6215-15-353.

42.

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.

Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PP, Nunn AJ; REMoxTB Consortium.

N Engl J Med. 2014 Oct 23;371(17):1577-87. doi: 10.1056/NEJMoa1407426. Epub 2014 Sep 7.

43.

Markers of inflammation: data from the MOSAIC randomised trial of CPAP for minimally symptomatic OSA.

Stradling JR, Craig SE, Kohler M, Nicoll D, Ayers L, Nunn AJ, Bratton DJ.

Thorax. 2015 Feb;70(2):181-2. doi: 10.1136/thoraxjnl-2014-205958. Epub 2014 Sep 2. Erratum in: Thorax. 2015 Apr;70(4):319.

PMID:
25182045
44.

Continuous positive airway pressure in older people with obstructive sleep apnoea syndrome (PREDICT): a 12-month, multicentre, randomised trial.

McMillan A, Bratton DJ, Faria R, Laskawiec-Szkonter M, Griffin S, Davies RJ, Nunn AJ, Stradling JR, Riha RL, Morrell MJ; PREDICT Investigators.

Lancet Respir Med. 2014 Oct;2(10):804-12. doi: 10.1016/S2213-2600(14)70172-9. Epub 2014 Aug 26.

45.

Dexamethasone and haemorrhage risk in paediatric tonsillectomy: a systematic review and meta-analysis.

Bellis JR, Pirmohamed M, Nunn AJ, Loke YK, De S, Golder S, Kirkham JJ.

Br J Anaesth. 2014 Jul;113(1):23-42. doi: 10.1093/bja/aeu152. Review.

46.

New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.

Zumla AI, Gillespie SH, Hoelscher M, Philips PP, Cole ST, Abubakar I, McHugh TD, Schito M, Maeurer M, Nunn AJ.

Lancet Infect Dis. 2014 Apr;14(4):327-40. doi: 10.1016/S1473-3099(13)70328-1. Review.

PMID:
24670627
47.

Prophylactic antibiotics to prevent cellulitis of the leg: economic analysis of the PATCH I & II trials.

Mason JM, Thomas KS, Crook AM, Foster KA, Chalmers JR, Nunn AJ, Williams HC.

PLoS One. 2014 Feb 14;9(2):e82694. doi: 10.1371/journal.pone.0082694. eCollection 2014.

48.

A clinical score (RAPID) to identify those at risk for poor outcome at presentation in patients with pleural infection.

Rahman NM, Kahan BC, Miller RF, Gleeson FV, Nunn AJ, Maskell NA.

Chest. 2014 Apr;145(4):848-855. doi: 10.1378/chest.13-1558.

PMID:
24264558
49.

Risk assessment of neonatal excipient exposure: lessons from food safety and other areas.

Turner MA, Duncan JC, Shah U, Metsvaht T, Varendi H, Nellis G, Lutsar I, Yakkundi S, McElnay JC, Pandya H, Mulla H, Vaconsin P, Storme T, Rieutord A, Nunn AJ.

Adv Drug Deliv Rev. 2014 Jun;73:89-101. doi: 10.1016/j.addr.2013.11.003. Epub 2013 Nov 13.

PMID:
24239480
50.

Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a pediatric hospital.

Bellis JR, Kirkham JJ, Thiesen S, Conroy EJ, Bracken LE, Mannix HL, Bird KA, Duncan JC, Peak M, Turner MA, Smyth RL, Nunn AJ, Pirmohamed M.

BMC Med. 2013 Nov 7;11:238. doi: 10.1186/1741-7015-11-238.

Supplemental Content

Support Center